ReviewMolecular medicine reports2026
Natural medicine‑empowered treatment of depression via restoring neurogenesis (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) remains a leading cause of disability, with a substantial proportion of patients failing to achieve adequate remission following conventional monoaminergic antidepressant treatment. The present narrative review examines evidence primarily published between 2015 and 2025 concerning natural medicines, including phytochemicals, traditional formulations, marine‑derived products and dietary polyphenols, that may modulate neurogenesis relevant to depression. Adult hippocampal neurogenesis is regarded as one mechanistic framework rather than the sole explanation for depressive pathology. Priority was given to clinical and human‑derived evidence, while preclinical studies are employed to elucidate underlying mechanisms. Natural products appear to converge on pathways involving brain‑derived neurotrophic factor/tropomyosin receptor kinase B, Wnt/β‑catenin, NF‑κB/NLR family pyrin domain containing 3‑mediated immune regulation, autophagy, mitochondrial bioenergetics and the gut microbiota. Nevertheless, current clinical evidence remains insufficient to support the use of natural medicines as substitutes for established antidepressant therapies. Their most plausible near‑term application lies in standardized adjunctive or investigational interventions, pending larger biomarker‑stratified trials, rigorous safety assessment and optimized formulation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.